As of April 23, Wind data reveals that securities traders have surveyed more than 400 listed companies since the beginning of the month. Among these, the electronics industry stands out with 60 companies surveyed, while the pharmaceutical and biological industry closely follows with 46 companies drawing attention. Institutions anticipate that the valuation of the electronics sector will expand due to various factors, advising investors to focus on allocation opportunities within this sector. Concurrently, the innovative drug segment within the pharmaceutical and biological industry also presents investment potential.
